Liver microRNA transcriptome reveals miR-182 as link between type 2 diabetes and fatty liver disease in obesity
Male
0301 basic medicine
obesity
QH301-705.5
Science
liver
Mice
Animals
Humans
human
Obesity
Biology (General)
2. Zero hunger
ddc:610
0303 health sciences
microRNA
Gene Expression Profiling
Q
R
Middle Aged
Fatty Liver
Mice, Inbred C57BL
MicroRNAs
Diabetes Mellitus, Type 2
Liver
Medicine
Female
type 2 diabetes
Transcriptome
DOI:
10.7554/elife.92075.1
Publication Date:
2023-12-01T13:23:46Z
AUTHORS (18)
ABSTRACT
The development of obesity-associated comorbidities such as type 2 diabetes (T2D) and hepatic steatosis has been linked to selected microRNAs in individual studies; however, an unbiased genome-wide approach map T2D induced changes the miRNAs landscape human liver samples, a subsequent robust identification validation target genes is still missing.Liver biopsies from age- gender-matched obese individuals with (n=20) or without were used for microRNA microarray analysis. candidate validated 85 subsequently mechanistically characterized cells well by dietary interventions overexpression mice.Here we present transcriptome use novel seed prediction tool robustly identify genes, which then unique cohort livers. Subsequent mouse studies identified distinct signature T2D-associated miRNAs, partly conserved both species. Of those, human-murine miR-182-5p was most associated whole-body glucose homeostasis lipid metabolism. Its gene LRP6 consistently lower expressed livers humans mice under conditions overexpression. Weight loss decreased restored Lrp6 expression other genes. Hepatic rapidly protein levels increased triglycerides fasting insulin obesogenic after only seven days.By mapping miRNA-transcriptome diabetic subjects, validating diet-induced mice, establishing miRNA tool, provide resource that will pave way future field. As proof concept, revealed repression miR-182-5p, promotes lipogenesis impairs homeostasis, provides mechanistic link between non-alcoholic fatty disease, demonstrate vivo can serve drug treatment obesity-driven steatosis.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (52)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....